Health · Medical Research · 8 hrs ago
Patient dies after Bristol Myers Squibb autoimmune CAR-T treatment
Bristol Myers Squibb reported that a patient died after receiving its experimental CAR-T therapy in a Phase 1 trial.
The trial was testing the treatment in people with multiple sclerosis, a condition that can cause muscle weakness and extreme fatigue.
The patient developed motor symptoms that did not improve with standard autoimmune treatments.
They were given a potent immunosuppressant, then developed septic pneumonia and died.
Bristol Myers Squibb said the patient had other complications before receiving the therapy, making it difficult to identify the root cause.
The death adds to safety concerns as research into CAR-T treatments for autoimmune diseases grows.
The information provided does not say what happens next in the trial.
Bristol Myers Squibb reported that a patient died after receiving its investigational CAR-T therapy in an early autoimmune trial.
The Phase 1 trial tested the therapy in people with multiple sclerosis.
The patient developed septic pneumonia after receiving a potent immunosuppressant and died, the company said.
Bristol Myers Squibb said complications before the therapy made it difficult to determine the root cause.
- Who
- A patient in Bristol Myers Squibb’s trial died.
- What
- The patient died after receiving the company’s investigational CAR-T therapy and later developing septic pneumonia.
- When
- Bristol Myers Squibb reported the death on Friday; the article was published on October 23, 2026.
- Where
- Not stated.
- Why
- The patient developed septic pneumonia after receiving a potent immunosuppressant. Bristol Myers Squibb said prior complications made the root cause difficult to determine.
This story does not have two clearly opposing sides.
The patient experienced motor symptoms that did not resolve with standard autoimmune treatments.
The patient received a potent immunosuppressant, developed septic pneumonia and died.
Bristol Myers Squibb reported the death.
- Trial phase
- Phase 1
- Condition studied
- Multiple sclerosis
- Reported cause of death
- Septic pneumonia
- Company
- Bristol Myers Squibb
- Publication date
- October 23, 2026
What people are saying
confounding our ability to determine the root cause of the issue.